{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:31:50Z","timestamp":1789835510197,"version":"4.0.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Advances in understanding disease pathogenesis have revealed a preclinical phase of inflammatory bowel disease (IBD), offering a potential window for preventive measures. There is growing interest in trials to prevent IBD in at-risk individuals. However, there is limited guidance on how to set up prevention trials in IBD. This review aims to outline key considerations for designing an IBD prevention trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izaf212","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:19:29Z","timestamp":1760343569000},"page":"S61-S70","source":"Crossref","is-referenced-by-count":1,"title":["How Should an IBD Prevention Trial Be Designed?"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1349-9501","authenticated-orcid":false,"given":"Rogier L","family":"Goetgebuer","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-3758","authenticated-orcid":false,"given":"Ryan C","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R A M","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2025101304192121200_izaf212-B1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cgh.2024.05.047","article-title":"Prediction and prevention of inflammatory bowel disease","volume":"23","author":"Lopes","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ueg2.12317","article-title":"Implications of the changing epidemiology of inflammatory bowel disease in a changing world","volume":"10","author":"Agrawal","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"2025101304192121200_izaf212-B3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2468-1253(24)00439-4","article-title":"Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design","volume":"10","author":"Honap","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2025101304192121200_izaf212-B5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41575-023-00854-4","article-title":"Deciphering the different phases of preclinical inflammatory bowel disease","volume":"21","author":"Rudbaek","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B7","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","author":"Kaplan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2025101304192121200_izaf212-B9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci Immunol"},{"key":"2025101304192121200_izaf212-B10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/eji.201545708","article-title":"Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes","volume":"46","author":"Tooley","year":"2016","journal-title":"Eur J Immunol"},{"key":"2025101304192121200_izaf212-B11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in Diabetes-2019","volume":"42","author":"American Diabetes A","year":"2019","journal-title":"Diabetes Care."},{"key":"2025101304192121200_izaf212-B12","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/dom.16246","article-title":"Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes","volume":"27","author":"O\u2019Donnell","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2025101304192121200_izaf212-B13","first-page":"3","article-title":"Evidence supporting the benefit of early intervention in rheumatoid arthritis","volume":"66","author":"Emery","year":"2002","journal-title":"J Rheumatol Suppl"},{"key":"2025101304192121200_izaf212-B14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"key":"2025101304192121200_izaf212-B15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"2025101304192121200_izaf212-B16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025101304192121200_izaf212-B17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","article-title":"Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial","volume":"69","author":"Bos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025101304192121200_izaf212-B18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025101304192121200_izaf212-B19","first-page":"1542","article-title":"Radiologically isolated syndrome: a review for neuroradiologists","volume":"41","author":"Hosseiny","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"2025101304192121200_izaf212-B20","doi-asserted-by":"crossref","first-page":"e90509","DOI":"10.1371\/journal.pone.0090509","article-title":"Radiologically isolated syndrome: 5-year risk for an initial clinical event","volume":"9","author":"Okuda","year":"2014","journal-title":"PLoS One"},{"key":"2025101304192121200_izaf212-B21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"2025101304192121200_izaf212-B22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann Neurol"},{"key":"2025101304192121200_izaf212-B23","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial","volume":"80","author":"Lebrun-Frenay","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025101304192121200_izaf212-B24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2024.08.031","article-title":"Healthy first-degree relatives from multiplex families vs simplex families have higher subclinical intestinal inflammation, a distinct fecal microbial signature, and harbor a higher risk of developing Crohn\u2019s disease","volume":"168","author":"Olivera","year":"2025","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B25","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.3748\/wjg.v12.i23.3668","article-title":"Family and twin studies in inflammatory bowel disease","volume":"12","author":"Halme","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025101304192121200_izaf212-B26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.gastro.2024.09.033","article-title":"Early life exposure to parental Crohn\u2019s disease is associated with offspring\u2019s gut microbiome, gut permeability, and increased risk of future Crohn\u2019s disease","volume":"168","author":"Lee","year":"2025","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/apt.18263","article-title":"Review article: prevention of inflammatory bowel disease-the path forward","volume":"60","author":"Bronze","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025101304192121200_izaf212-B28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ecco-jcc\/jjv197","article-title":"IBD genetic risk profile in healthy first-degree relatives of Crohn\u2019s disease patients","volume":"10","author":"Kevans","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2025101304192121200_izaf212-B29","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cgh.2023.12.020","article-title":"Per- and Poly-Fluoroalkyl substances exposure is associated with later occurrence of inflammatory bowel disease","volume":"22","author":"Agrawal","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.gastro.2022.09.007","article-title":"Inflammatory bowel disease is associated with prediagnostic perturbances in metabolic pathways","volume":"164","author":"Hua","year":"2023","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B31","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1016\/j.cgh.2023.01.033","article-title":"Preclinical serological signatures are associated with complicated Crohn\u2019s disease phenotype at diagnosis","volume":"21","author":"Choung","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/gutjnl-2022-328421","article-title":"Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn\u2019s disease highlight earliest events of pathogenesis","volume":"72","author":"Leibovitzh","year":"2023","journal-title":"Gut"},{"key":"2025101304192121200_izaf212-B33","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1053\/j.gastro.2021.07.009","article-title":"Anti-microbial antibody response is associated with future onset of Crohn\u2019s disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk","volume":"161","author":"Lee","year":"2021","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/j.gastro.2022.05.029","article-title":"Neutralizing anti-granulocyte macrophage-colony stimulating factor autoantibodies recognize post-translational glycosylations on granulocyte macrophage-colony stimulating factor years before diagnosis and predict complicated Crohn\u2019s disease","volume":"163","author":"Mortha","year":"2022","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1053\/j.gastro.2020.08.005","article-title":"Increased intestinal permeability is associated with later development of Crohn\u2019s disease","volume":"159","author":"Turpin","year":"2020","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B36","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1053\/j.gastro.2022.07.004","article-title":"Altered gut microbiome composition and function are associated with gut barrier dysfunction in healthy relatives of patients with Crohn\u2019s disease","volume":"163","author":"Leibovitzh","year":"2022","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2024.08.021","article-title":"Development and validation of an integrative risk score for future risk of Crohn\u2019s disease in healthy first-degree relatives: a multicenter prospective cohort study","volume":"168","author":"Lee","year":"2025","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B38","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/ecco-jcc\/jjaa111","article-title":"Validation of the red flags index for early diagnosis of Crohn\u2019s disease: a prospective observational IG-IBD study among general practitioners","volume":"14","author":"Fiorino","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025101304192121200_izaf212-B39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2019.05.061","article-title":"Genetic and inflammatory biomarkers classify small intestine inflammation in asymptomatic first-degree relatives of patients with Crohn\u2019s disease","volume":"18","author":"Taylor","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cgh.2017.02.028","article-title":"Increased intestinal permeability in relatives of patients with Crohn\u2019s disease is not associated with small bowel ulcerations","volume":"15","author":"Teshima","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025101304192121200_izaf212-B41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.dld.2020.07.036","article-title":"Inflammatory bowel disease in a colorectal cancer screening population: diagnosis and follow-up","volume":"53","author":"Bezzio","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2025101304192121200_izaf212-B42","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2021.07.051","article-title":"Is prevention the best way to modify inflammatory bowel disease? How close are we?","volume":"162","author":"Torres","year":"2022","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2025101304192121200_izaf212-B44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025101304192121200_izaf212-B45","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025101304192121200_izaf212-B46","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1128\/AAC.48.8.2787-2792.2004","article-title":"Hazard ratio in clinical trials","volume":"48","author":"Spruance","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025101304192121200_izaf212-B47","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/annrheumdis-2021-220884","article-title":"EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis","volume":"80","author":"Mankia","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025101304192121200_izaf212-B48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.crohns.2011.01.008","article-title":"Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)","volume":"5","author":"Aguas","year":"2011","journal-title":"J Crohns Colitis"},{"key":"2025101304192121200_izaf212-B49","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B50","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis","volume":"164","author":"Singh","year":"2023","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ajg.2015.50","article-title":"Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011","volume":"110","author":"Moller","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025101304192121200_izaf212-B53","first-page":"14","article-title":"Familial and ethnic risk in inflammatory bowel disease","volume":"31","author":"Santos","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2025101304192121200_izaf212-B54","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.gastro.2024.11.006","article-title":"Preclinical protein signatures of Crohn\u2019s disease and ulcerative colitis: a nested case-control study within large population-based cohorts","volume":"168","author":"Granno","year":"2025","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-Integrin alphavbeta6 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","article-title":"Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis","volume":"159","author":"Torres","year":"2020","journal-title":"Gastroenterology"},{"key":"2025101304192121200_izaf212-B57","doi-asserted-by":"crossref","first-page":"e010555","DOI":"10.1136\/bmjopen-2015-010555","article-title":"Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study","volume":"6","author":"Stack","year":"2016","journal-title":"BMJ Open"},{"key":"2025101304192121200_izaf212-B58","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/acr.23841","article-title":"I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis","volume":"72","author":"Mosor","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025101304192121200_izaf212-B59","author":"Rev\u00e9s"},{"key":"2025101304192121200_izaf212-B60","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/acr2.11500","article-title":"Preferences and insights for participation in a rheumatoid arthritis clinical prevention trial: a mixed-methods study","volume":"4","author":"Fleischer","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025101304192121200_izaf212-B61","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa012350","article-title":"Effects of insulin in relatives of patients with type 1 diabetes mellitus","volume":"346","author":"Diabetes Prevention Trial\u2014Type 1 Diabetes Study Group","year":"2002","journal-title":"N Engl J Med"},{"key":"2025101304192121200_izaf212-B62","author":"Raad Volksgezondheid Samenleving.","year":"2025"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/Supplement_2\/S61\/64655750\/izaf212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/Supplement_2\/S61\/64655750\/izaf212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:19:37Z","timestamp":1760343577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/Supplement_2\/S61\/8284734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":62,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf212","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,24]]}}}